Holdings
Lynx1 Capital Management LP
As of Sep 30, 2026, Lynx1 Capital Management LP reported 27 positions worth US$331M. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and C4 Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc. | 8.96M | US$138M | no change | Sep 30, 2026 |
| Stoke Therapeutics, Inc. | 3.9M | US$101M | −142K | Sep 30, 2026 |
| C4 Therapeutics, Inc. | 7.53M | US$25.1M | +204K | Sep 30, 2026 |
| Precision BioSciences, Inc. | 2.76M | US$17.3M | +1.81M | Sep 30, 2026 |
| Agios Pharmaceuticals, Inc. | 473K | US$15.7M | −2.94M | Sep 30, 2026 |
| Korro Bio, Inc. | 1.54M | US$15.3M | +6,684 | Sep 30, 2026 |
| Neuphoria Therapeutics Inc. | 875K | US$3.12M | no change | Sep 30, 2026 |
| Passage Bio, Inc. | 674K | US$3.03M | no change | Sep 30, 2026 |
| TScan Therapeutics, Inc. | 8.02M | US$2.52M | no change | Sep 30, 2026 |
| Kazia Therapeutics Ltd | 226K | US$2.17M | new | Sep 30, 2026 |